Thyreosvaccines
1 known investors
Thyreos develops prophylactic vaccines targeting neuroinvasive herpesvirus infections.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $297.5K |
| Department of Agriculture (USDA) | Phase I | 2022 | $174.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Thyreosvaccines do?
- Thyreos develops prophylactic vaccines targeting neuroinvasive herpesvirus infections.
- Who are Thyreosvaccines's investors?
- Thyreosvaccines's investors include Invest Nebraska.